Publication
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Authors not recorded
Nat Commun2025PMID 40691143PMC12280041stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerMalignant Mesotheliomacivic_curation1.00
- drugNivolumabcivic_curation1.00
- variantLowcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40691143
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Low1 | ||||||||
| Nivolumab | Malignant Mesothelioma | Predictive | B | Does Not Support Sensitivity Response | 1 | accepted | EID12918This is part of a randomised phase 3 trial, CheckpOiNt Blockade For the Inihibition of Relapsed Mesothelioma (CONFIRM), that examined therapeutic response to the anti-PD1 inhibitor, nivolumab, in pati… (full text at CIViC) PMID 40691143 · Fennell et al., 2025 · Open in CIViC | civic |